Probiodrug pursues modified abeta approach to tackle Alzheimer's- Dr. Konrad Glund, CEO, Probiodrug 00:00:00
Probiodrug AG CEO Dr. Konrad Glund tells Mike Ward, global director of content for Informa's pharma insights portfolio, about his company's differentiated approach to targeting Alzheimer's disease.